Disitamab Vedotin Benefits Linked to HER-2 in Urothelial Cancer
In a groundbreaking multi-center, real-world study recently published in BMC Cancer, researchers unveil critical insights into the clinical efficacy of Disitamab Vedotin (DV), a novel...












